Weijie Wang

Weijie Wang is a seasoned professional in the field of Chemistry with a Ph.D. from the University of Alberta, obtained between 1999 and 2004. Currently serving as Sr. Director of CMC & Analytical Development at Oncternal Therapeutics since April 2021, Weijie has held significant roles in various organizations, including Director positions at both Gilead Sciences and Forty Seven Inc., as well as Director of Analytical Development at Incyte. Previous experience includes serving as Principal Scientist at Teva Pharmaceuticals and Sr. Scientist I at Human Genome Sciences, along with a role as Scientist at Calibrant Biosystems.